Page 3 - Breaking Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The meeting, cohosted by the World Heart Federation, will have a “distinct international flavor” beyond the late-breaking fare.

The trial missed its primary endpoint, but makes unique contributions; many see it as further evidence that the treatment helps iron-deficient patients with heart failure.

CHICAGO — Use of a point-of-care tool to support clinical decision-making in addition to rapid outpatient follow-up reduced the risk for death or CV hospitalizations for patients with acute HF presenting to the ED. “Implementation of this approach may lead to a pathway for early discharge from the hospital or emergency department and improved patient outcomes,” Douglas S. Lee,

CHICAGO — A novel CRISPR-based in vivo gene editing therapy reduced transthyretin levels in patients with hereditary transthyretin amyloidosis with cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a “progressive and fatal disease,” during which amyloid deposits cause impaired

Planners see the meeting's Chicago return as a hybrid after 2 years relegated to cyberspace as a chance for first impressions on some just entering the field.